Trilok Shrivastava

Assistant Professor

UAMS

Also affiliated: John H. Stroger, Jr. Hospital of Cook County (2020–2022); RKDF University (2024); Winthrop Rockefeller Foundation (2023–2025); People’s University (2012–2021); Kathmandu Medical College Teaching Hospital (2017)

Faculty Researcher

COM | Internal Med Hem-Onc

4 h-index 54 pubs 80 cited

Research Areas

Links

ORCID UAMS TRI Profile

OverviewAI-generated summary

Trilok Shrivastava's research focuses on hematologic malignancies, particularly multiple myeloma. His work investigates treatment strategies, patient outcomes, and the psychological impact of these diseases. He has published on topics including the psychological effects of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma, as well as the role of B cell maturation antigen targeting therapies in multiple myeloma patients. Shrivastava also explores T cell subsets as predictors of response to bispecific antibody therapy and T cell redirecting therapy post-stem cell transplantation for relapsed multiple myeloma. His research interests extend to other areas, including a meta-analysis on thromboprophylaxis in COVID-19 patients and a case report on teclistamab for idiopathic immune thrombocytopenia in multiple myeloma patients. Shrivastava's work is supported by collaborations with researchers at the University of Arkansas for Medical Sciences, including Ramya Bachu and Tanvi H Patel.

Metrics

h-index: 4
Publications: 54
Citations: 80

Selected Publications

Inpatient CAR-T safety in the United States: Severe ICANS and CRS by donor source and antigen target (NIS 2022–2023). (2026)

Journal of Clinical Oncology DOI OpenAlex
Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma. (2026)

Journal of Clinical Oncology DOI OpenAlex
Stage-dependent divergence of immune prognostic signatures in non–small cell lung cancer. (2026)

Journal of Clinical Oncology DOI OpenAlex
Predictors of low- and high-grade ICANS after CAR-T: A nationwide analysis. (2026)

Journal of Clinical Oncology DOI OpenAlex
Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma (2025)

Frontiers in Hematology 1 citation DOI OpenAlex
Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP) (2024)

Blood DOI OpenAlex
Psychological Impact in Individuals with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma (2024)

Clinical Hematology International 12 citations DOI OpenAlex
Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma. (2024)

Journal of Clinical Oncology 2 citations DOI OpenAlex
A Single Center Experience of T Cell Redirecting Therapy Post Stem Cell Transplantation in Relapsed Multiple Myeloma (2024)

Transplantation and Cellular Therapy 1 citation DOI OpenAlex
Psychological Impact in Individuals with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma (2023)

Blood DOI OpenAlex
Sixth Nerve Palsy From Multiple Myeloma in Central Nervous System: Case Series and Review of Current Literature (2023)

Cureus 2 citations DOI OpenAlex
Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives (2023)

OncoTargets and Therapy 11 citations DOI OpenAlex